OncoCyte Corporation

10:45 AM - 11:00 AM, Wednesday, June 5, 2019 ・ Theater 2
OncoCyte is focused on the development and commercialization of novel, non-invasive blood (“liquid biopsy”) diagnostic tests for the early detection of cancer. Early detection of cancer can improve health outcomes, reduce the cost of care, and improve patients’ quality of life. Liquid biopsy diagnostic tests like those OncoCyte is developing may reduce the need for costlier and riskier diagnostic procedures such as invasive biopsy procedures. OncoCyte is focusing its efforts on developing DetermaVu™ as a non-invasive confirmatory diagnostic test for lung cancer. DetermaVu™ is being developed using proprietary sets of genetic and protein molecular markers to detect the presence of lung cancer. OncoCyte also plans to conduct research to identify additional molecular markers, acquire or license markers and related technology, and develop cancer tests based on those markers.
Ticker:
OCX
Exchange:
NYSE American
Company Type:
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2009
Main Therapeutic Focus:
Lead Product in Development:
DetermaVu
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided.
Speaker
photo
CEO
OncoCyte Corporation